HIV Researchers Early-Stage Investigators (ESIs) Mentoring Workshop Opportunity

The National Centers for AIDS Research (CFAR) is hosting an ESI Mentoring Workshop on November 9 during the 27th National CFAR Meeting (November 7-9), 2023. ESI attendees can participate in the CFAR Scientific Symposium, ESI Poster Session, and CFAR Leadership Dinner.

The NIH defines an ESI as: A Program Director / Principal Investigator (PD/PI) who has completed their terminal research degree or end of post-graduate clinical training, whichever date is later, within the past 10 years and who has not previously compete successfully as PD/PI for a substantial NIH independent research award. See list of NIH grants that a PD/PI can hold and still be considered an ESI: https://grants.nih.gov/policy/early-investigators/list-smaller-grants.htm

**NOTE** For this Mentoring Workshop Opportunity: ESI is defined as “investigators who have not yet received independent NIH R01 or equivalent funding in HIV/AIDS-related clinical, behavioral, public health, or laboratory research” whether or not they are within 10 years of completing their training.

The Texas Developmental CFAR (D-CFAR) can nominate one ESI to attend the meeting on a travel scholarship. The scholarship will provide airfare, up to 3 nights lodging, local travel, and meals for each nominated EST. The Texas D-CFAR will support an additional ESI to attend the Meeting and all its activities.

Texas D-CFAR ESIs who are interested in attending the Meeting should submit an Abstract and NIH Biosketch by 5:00 PM August 11. Abstract Guidelines are attached.
# Suggested Abstract Submission Guidelines

The following guidelines are offered to assist CFARs that are inviting their Early-Stage Investigators to participate in the National CFAR Meeting in Baltimore in November 2023.

<table>
<thead>
<tr>
<th>Eligibility</th>
<th>Early-Stage Investigators (ESI) are defined as those who have not yet received independent NIH R01 or equivalent funding in HIV/AIDS-related clinical, behavioral, public health, or laboratory research.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restrictions</td>
<td>At the discretion of each CFAR.</td>
</tr>
<tr>
<td>Procedure</td>
<td>Interested ESIs are invited to submit abstracts to their respective CFARs for competitive selection to attend the National CFAR Scientific Symposium and participate in the Early-Stage Investigator poster session and workshop during the 2023 National CFAR Meeting in Baltimore, November 7-9. In addition, one or more of the selected abstracts will be chosen for brief oral presentation(s) during the Scientific Symposium as well as the poster session. The Johns Hopkins CFAR will support travel expenses for one ESI per CFAR site. Additional ESI expenses must be fully covered by their respective CFARs.</td>
</tr>
</tbody>
</table>
| ABSTRACT FORMAT | **Heading**

1. **Title:** Use a concise title that indicates the content of the abstract.

2. **Authors:** Authors’ names should be typed in upper- and lowercase letters (please do not use all capital letters). Use first name and last name. Indicate the presenting author and include an email address and business phone. There is a limit of 10 authors per abstract.

3. **Affiliations:** List institution, city, and state for domestic authors. List institution, city, and country for international authors. Do not include department, division, laboratory, or acknowledgements.

4. **Funding source:** List funding source(s) and grant number(s).

**Content**

Abstracts are welcome on all aspects of HIV/AIDS clinical, behavioral, public health, or laboratory research. As a suggestion, the National CFAR Scientific Symposium is focusing on:

- Aging with HIV across the Lifespan
- HIV and Drug User health
- Co-Morbidities (TB, Hep B, Cancer)
- Cure
- EHE/Implementation Science

Abstracts are limited to 2,500 characters, including spaces. A maximum of one table or one figure may be included. Please do not include literature references or copyright or trademark symbols. Please bold the following four section headings within the text of your abstract.

**Background:** A concise statement of the issue under investigation or a hypothesis.

**Methods:** The experimental methods used (including the statistical analyses employed).

**Results:** Specific findings (promises such as “to be completed” or “to be presented” are not acceptable).

**Conclusions:** A summary of findings that are supported by your results. (Statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as “the results will be discussed” are not acceptable.)